Evidence map›Paper›PMID 40127942›Full record

ArticleBMJ global health2025

The long-term impact of the COVID-19 pandemic on tuberculosis care and infection control measures in anti-retroviral therapy (ART) clinics in low- and middle-income countries: a multiregional site survey in Asia and Africa.

Marie Ballif, Nicolas Banholzer, Lisa Perrig, Anchalee Avihingsanon, Dominique Mahambu Nsonde, Sarah Obatsa, Guy Muula, Eric Komena, Haruka Uemura, Patricia Lelo and 15 more

Abstract read
In one paragraph

Article in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Marie Ballif *Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Nicolas Banholzer *Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Lisa PerrigInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Anchalee AvihingsanonHIV-NAT / Thai Red Cross AIDS Research Centre and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Dominique Mahambu NsondeCentre de Traitement Ambulatoire, Brazzaville, Republic of Congo.
Sarah ObatsaCentre for Microbiology and Research, Kenya Medical Research Institute, Kisumu, Kenya.
Guy MuulaCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Eric KomenaPAC-CI program, Abidjan, Côte d'Ivoire.
Haruka UemuraAIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Patricia LeloPediatric Hospital of Kalembelembe, Kinshasa, Democratic Republic of the Congo.
Brian OtaaloInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Jacqueline HuwaLighthouse Trust, Lilongwe, Malawi.
Patrice GouésséCePReF, Abidjan, Côte d'Ivoire.
Nagalingeswaran KumarasamyCART Clinical Research Site, Voluntary Health Services, Chennai, India.
Ellen BrazierCity University of New York, Institute for Implementation Science in Population Health, New York, NY, USA.
Denna MichaelKisesa Observation Cohort study, National Institute for Medical Reseach, Mwanza, Tanzania.
Idiovino RafaelSolidarMed, Chiure, Mozambique.
Richard RamdéCHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso.
I Ketut Agus SomiaFaculty of Medicine, Udayana University, Ngoerah Hospital, Bali, Indonesia.
Marcel YotebiengDivision of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0003-2110-2631
Lameck DieroDepartment of Medicine, Moi University, AMPATH Program / Moi Teaching and Referral Hospital, Eldoret, Kenya.
Jonathan EuvrardSchool of Public Health, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-3937-7855
Oliver EzechiCentre for Reproduction and Population Health Studies, Nigerian Institute of Medical Research, Lagos, Nigeria.ORCID http://orcid.org/0009-0003-1595-2506
Lukas FennerInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland lukas.fenner@unibe.ch.ORCID http://orcid.org/0000-0003-3309-4835
Global IeDEA consortium

Funding

North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Leslie Anne Enane, AGGREY SEMWENDERO SEMEERE · 2006 to 2026
$57.7M
Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
"Enhancing Cancer Research in Central Africa IeDEA"U01AI096299 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Denis Nash, Marcel Yotebieng · 2011 to 2026
$35.8M
WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
Harmonist: A Scalable Toolkit for Standardizing and Coordinating Data Sharing Across International Research NetworksR24AI124872 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Stephany Norah Duda · 2016 to 2026
$12.5M
NIAID NIH HHS R24 AI124872NIAID NIH HHS U01 AI069907NIAID NIH HHS U01 AI069911NIAID NIH HHS U01 AI069918NIAID NIH HHS U01 AI069919NIAID NIH HHS U01 AI069924NIAID NIH HHS U01 AI096299
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic challenged healthcare systems, particularly in settings with high infectious disease burden. We examined the postpandemic long-term impacts of COVID-19 on tuberculosis (TB) services at anti-retroviral therapy (ART) clinics in lower-income countries.

methodsUsing standardised online questionnaires, we conducted a cross-sectional site survey among ART clinics providing TB services in Africa and Asia from July to September 2023 (site-level information and number of TB diagnoses and tests).

resultsOf 45 participating ART clinics, 32 (71%) were in Africa and 13 (29%) in Asia. During the COVID-19 pandemic (2020-2022), 43 (96%) clinics reported implementing social distancing or separation measures, 39 (87%) personal protections for staff members and 32 (71%) protections for patients. Infection control measures were in place in 45% of the clinics before the pandemic (until 2019), 23% introduced measures during the pandemic and 15% maintained them after the pandemic (after 2022). Service provision was affected during the pandemic in 33 (73%) clinics, including TB services in 22 (49%) clinics. TB service restrictions were addressed by introducing changes in directly observed therapy provision in 8 (18%) clinics, multimonth TB drug dispensing in 23 (51%), telehealth services in 25 (56%) and differentiated service delivery in 19 (42%). These changes were sustained after the pandemic at 4 (9%), 11 (24%), 17 (38%) and 12 (27%) clinics, respectively. Compared with 2018-2019, the number of TB diagnoses decreased sharply in 2020-2021 and improved after the pandemic.

conclusionsCOVID-19 affected TB care services in ART clinics in Africa and Asia. This was paralleled by a reduction in TB diagnoses, which partly resumed after the pandemic. Infection control measures and alternative modes of service delivery were adopted during the pandemic and only partially maintained. Efforts should be made to sustain the lessons learnt during the COVID-19 pandemic, particularly approaches that reduce the risk of transmission of infectious diseases, including TB, in ART clinics.

Indexed as

Ambulatory Care FacilitiesAnti-Retroviral AgentsCOVID-19HIV InfectionsInfection ControlTuberculosisAfricaAsiaCross-Sectional StudiesDeveloping CountriesHumansSARS-CoV-2Surveys and QuestionnairesAnti-Retroviral AgentsCOVID-19HIVTuberculosis

Identifiers

PMID40127942
PMCPMC11934364

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.